Acceleron, Celgene Announce Preliminary Results From Sotatercept Phase 2 Study

Acceleron Pharma Inc. (XLRN) and Celgene Corp. (CELG) announced preliminary results from an ongoing investigator initiated Phase 2 study with investigational drug sotatercept in patients with myelofibrosis at the 58th Annual Meeting of the American Society of Hematology or ASH in San Diego, California.

from RTT - Biotech http://ift.tt/2gY3tNA
via IFTTT